The limited value of methylmalonic acid, homocysteine and holotranscobalamin in the diagnosis of early B12 deficiency

Department of Haematology, University Hospital of Wales, Cardiff CF14 4XN, UK.

Treatment of B12 deficiency is important to prevent progressive neurological and/or hematologic disease but requires a secure diagnosis. The aim of this study was to evaluate second line tests of B12 status as prognostic indicators of a hematologic response to vitamin B12 therapy. Forty-nine patients referred with low, serum vitamin B12 concentrations were treated with intramuscular B12 and re-assessed after 3 months. Methylmalonic acid, homocysteine, holotranscobalamin and neutrophil hypersegmentation index were measured before and after treatment. Before treatment 27/49 patients were anemic or macrocytic of whom 15 had a clear hematologic response. All the tests had a similar prognostic accuracy. Symptomatic improvement did not correlate with hematologic response. Supplementary tests of vitamin B12 status were not significantly better than total serum B12 concentration as predictors of a hematologic response to vitamin B12 therapy.

This article has been cited by other articles:

				M. Galloway and M. Hamilton Macrocytosis: pitfalls in testing and summary of guidance BMJ, October 27, 2007; 335(7625): 884 - 886. [Full Text] [PDF]